U.S. markets closed

Hyundai Bioscience Co., Ltd. (048410.KQ)

KOSDAQ - KOSDAQ Delayed Price. Currency in KRW
29,200.00+150.00 (+0.52%)
At close: 03:30PM KST

Hyundai Bioscience Co., Ltd.

150, Bugahyeon-ro
3rd Floor Seodaemun-gu
Seoul 03759
South Korea
82 1 544 3194

Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Jong-Won ChoiJoint Chief Executive OfficerN/AN/A1967
Ho-Suk ChonJoint Chief Executive OfficerN/AN/A1958
Yeong-Jin KimPresidentN/AN/A1970
Seok-Yong ChoiChief Operating Officer and Senior Managing DirectorN/AN/A1962
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in KRW.


Hyundai Bioscience Co., Ltd. operates as a biotechnology company. The company provides Vitabrid C12, a vitamin C product that delivers active vitamin C into the skin. It develops Polytaxel, a drug for pancreatic cancer and solid tumors; and CP-COV03 drug for Covid 19. The company was founded in 2000 and is based in Seoul, South Korea.

Corporate Governance

Hyundai Bioscience Co., Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.